Chronic obstructive pulmonary disease (COPD) management has evolved with the emergence of advanced pharmacological strategies, notably dual bronchodilation and bifunctional agents. Among these innovations, the selective inhaled phosphodiesterase (PDE)3/4 inhibitor ensifentrine represents a novel therapeutic class that combines bronchodilatory and anti-inflammatory properties within a single molecular entity. Dual bronchodilation, traditionally achieved through the combination of long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists, has demonstrated superior efficacy compared with monotherapies, including enhanced pulmonary function, reduced symptom burden, and decreased exacerbation frequency. Ensifentrine, recently approved by the US Food and Drug Administration, exerts bronchodilation via PDE3 inhibition and suppresses inflammation by inhibiting PDE4, offering complementary benefits when combined with LAMAs. Clinical trials, including ENHANCE-1 and ENHANCE-2, have shown that ensifentrine significantly improves FEV1, reduces exacerbations, and lowers inflammatory biomarkers, with a favorable safety profile. Notably, preclinical and clinical data suggest synergism between ensifentrine and muscarinic antagonists, underpinning the rationale for a combination approach. This has led to the conceptualization of "trifunctional dual bronchodilation," describing a regimen that simultaneously targets distinct bronchodilatory mechanisms and provides robust anti-inflammatory effects. Such a strategy may support corticosteroid stewardship by reducing inhaled corticosteroid use, particularly in patients with low eosinophil counts or corticosteroid resistance. However, limitations remain, including the absence of head-to-head trials against existing triple therapy, high cost, and reliance on nebulized delivery. Future research should evaluate long-term outcomes, optimal placement within treatment algorithms, and potential benefits of dry powder or metered-dose formulations. Overall, ensifentrine, especially in combination with a LAMA, may redefine maintenance therapy in COPD, offering a steroid-sparing alternative grounded in mechanistic synergy and clinical efficacy.
Cazzola et al. (Thu,) studied this question.